Literature DB >> 12021329

Effects of antiretroviral drugs on human immunodeficiency virus type 1-induced CD4(+) T-cell death.

Jérôme Estaquier1, Jean-Daniel Lelièvre, Frédéric Petit, Thomas Brunner, Laure Moutouh-De Parseval, Douglas D Richman, Jean Claude Ameisen, Jacques Corbeil.   

Abstract

Apoptosis of peripheral blood T cells plays an important role in the pathogenesis of human immunodeficiency virus (HIV) infection. In this study, we found that HIV type 1 (HIV-1) primes CD4(+) T cells from healthy donors for apoptosis, which occurs after CD95 ligation or CD3-T-cell receptor (TCR) stimulation. CD95-mediated death did not depend on CD4 T-cell infection, since it occurred in the presence of the reverse transcriptase inhibitor didanosine (ddI). In contrast, apoptosis induced by productive infection (CD3-TCR stimulation) is prevented by both CD95 decoy receptor and ddI. Our data suggest that HIV-1 triggers at least two distinct death pathways: a CD95-dependent pathway that does not require viral replication and a viral replication-mediated cell death independent of the CD95 pathway. Further experiments indicated that saquinavir, a protease inhibitor, at a 0.2 microM concentration, decreased HIV-mediated CD95 expression and thus cell death, which is independent of its role in inhibiting viral replication. However, treatment of peripheral blood mononuclear cells from healthy donors with a higher concentration (10 microM) of an HIV protease inhibitor, saquinavir or indinavir, induced both a loss in mitochondrial membrane potential (DeltaPsim) and cell death. Thus, protease inhibitors have the potential for both beneficial and detrimental effects on CD4(+) T cells independent of their antiretroviral effects.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12021329      PMCID: PMC136220          DOI: 10.1128/jvi.76.12.5966-5973.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  60 in total

1.  Protease inhibitors stimulate hematopoiesis and decrease apoptosis and ICE expression in CD34(+) cells.

Authors:  E M Sloand; J Maciejewski; P Kumar; S Kim; A Chaudhuri; N Young
Journal:  Blood       Date:  2000-10-15       Impact factor: 22.113

2.  Prediction of imminent complications in HIV-1-infected patients by markers of lymphocyte apoptosis.

Authors:  J C Wasmuth; K H Klein; F Hackbarth; J K Rockstroh; T Sauerbruch; U Spengler
Journal:  J Acquir Immune Defic Syndr       Date:  2000-01-01       Impact factor: 3.731

3.  Effect of combination antiretroviral therapy upon rectal mucosal HIV RNA burden and mononuclear cell apoptosis.

Authors:  D P Kotler; T Shimada; G Snow; G Winson; W Chen; M Zhao; Y Inada; F Clayton
Journal:  AIDS       Date:  1998-04-16       Impact factor: 4.177

4.  Anti-retroviral therapy reverses HIV-associated abnormalities in lymphocyte apoptosis.

Authors:  N Johnson; J M Parkin
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

5.  Diminished spontaneous apoptosis in lymphocytes from human immunodeficiency virus-infected long-term nonprogressors.

Authors:  T J Liegler; W Yonemoto; T Elbeik; E Vittinghoff; S P Buchbinder; W C Greene
Journal:  J Infect Dis       Date:  1998-09       Impact factor: 5.226

6.  Decreased HIV-associated T cell apoptosis by HIV protease inhibitors.

Authors:  B N Phenix; J B Angel; F Mandy; S Kravcik; K Parato; K A Chambers; K Gallicano; N Hawley-Foss; S Cassol; D W Cameron; A D Badley
Journal:  AIDS Res Hum Retroviruses       Date:  2000-04-10       Impact factor: 2.205

7.  Decreased CD95 expression on naive T cells from HIV-infected persons undergoing highly active anti-retroviral therapy (HAART) and the influence of IL-2 low dose administration. Irhan Study Group.

Authors:  A Amendola; F Poccia; F Martini; C Gioia; V Galati; M Pierdominici; M Marziali; F Pandolfi; V Colizzi; M Piacentini; E Girardi; G D'offizi
Journal:  Clin Exp Immunol       Date:  2000-05       Impact factor: 4.330

8.  Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study.

Authors:  R P van Heeswijk; A I Veldkamp; J W Mulder; P L Meenhorst; J M Lange; J H Beijnen; R M Hoetelmans
Journal:  AIDS       Date:  2000-06-16       Impact factor: 4.177

9.  Role of Fas ligand and receptor in the mechanism of T-cell depletion in acquired immunodeficiency syndrome: effect on CD4+ lymphocyte depletion and human immunodeficiency virus replication.

Authors:  E M Sloand; N S Young; P Kumar; F F Weichold; T Sato; J P Maciejewski
Journal:  Blood       Date:  1997-02-15       Impact factor: 22.113

10.  Early T-cell apoptosis and Fas expression during antiretroviral therapy in individuals infected with human immunodeficiency virus-1.

Authors:  S P Aries; K Weyrich; B Schaaf; F Hansen; R H Dennin; K Dalhoff
Journal:  Scand J Immunol       Date:  1998-07       Impact factor: 3.487

View more
  18 in total

1.  Inhibition of adenine nucleotide translocator pore function and protection against apoptosis in vivo by an HIV protease inhibitor.

Authors:  Joel G R Weaver; Agathe Tarze; Tia C Moffat; Morgane Lebras; Aurelien Deniaud; Catherine Brenner; Gary D Bren; Mario Y Morin; Barbara N Phenix; Li Dong; Susan X Jiang; Valerie L Sim; Bogdan Zurakowski; Jessica Lallier; Heather Hardin; Peter Wettstein; Rolf P G van Heeswijk; Andre Douen; Romano T Kroemer; Sheng T Hou; Steffany A L Bennett; David H Lynch; Guido Kroemer; Andrew D Badley
Journal:  J Clin Invest       Date:  2005-07       Impact factor: 14.808

Review 2.  HIV protease inhibitors impact on apoptosis.

Authors:  Stacey A Rizza; Andrew D Badley
Journal:  Med Chem       Date:  2008-01       Impact factor: 2.745

3.  Replication-independent expression of anti-apoptosis marker genes in human peripheral blood mononuclear cells infected with the wild-type HIV-1 and reverse transcriptase variants.

Authors:  Prem L Sharma; Himabindu Chunduri; Jasen Wise; Rondeen Mindley; David Rimland
Journal:  Viral Immunol       Date:  2012-01-12       Impact factor: 2.257

4.  Distinct mechanisms of CD4+ and CD8+ T-cell activation and bystander apoptosis induced by human immunodeficiency virus type 1 virions.

Authors:  Geoffrey H Holm; Dana Gabuzda
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

5.  Cellular Redox Profiling Using High-content Microscopy.

Authors:  Tom Sieprath; Tobias Corne; Joke Robijns; Werner J H Koopman; Winnok H De Vos
Journal:  J Vis Exp       Date:  2017-05-14       Impact factor: 1.355

6.  The anti-caspase inhibitor Q-VD-OPH prevents AIDS disease progression in SIV-infected rhesus macaques.

Authors:  Mireille Laforge; Ricardo Silvestre; Vasco Rodrigues; Julie Garibal; Laure Campillo-Gimenez; Shahul Mouhamad; Valérie Monceaux; Marie-Christine Cumont; Henintsoa Rabezanahary; Alain Pruvost; Anabela Cordeiro-da-Silva; Bruno Hurtrel; Guido Silvestri; Anna Senik; Jérôme Estaquier
Journal:  J Clin Invest       Date:  2018-03-19       Impact factor: 14.808

7.  Apoptosis of bystander T cells induced by human immunodeficiency virus type 1 with increased envelope/receptor affinity and coreceptor binding site exposure.

Authors:  Geoffrey H Holm; Chengsheng Zhang; Paul R Gorry; Keith Peden; Dominique Schols; Erik De Clercq; Dana Gabuzda
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  Nelfinavir, an HIV-1 protease inhibitor, induces oxidative stress-mediated, caspase-independent apoptosis in Leishmania amastigotes.

Authors:  Pranav Kumar; Robert Lodge; Nathalie Trudel; Michel Ouellet; Marc Ouellette; Michel J Tremblay
Journal:  PLoS Negl Trop Dis       Date:  2010-03-30

9.  Distinct cycling CD4(+)- and CD8(+)-T-cell profiles during the asymptomatic phase of simian immunodeficiency virus SIVmac251 infection in rhesus macaques.

Authors:  V Monceaux; R Ho Tsong Fang; M C Cumont; B Hurtrel; J Estaquier
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

10.  HIV protease inhibitors provide neuroprotection through inhibition of mitochondrial apoptosis in mice.

Authors:  Toshio Hisatomi; Toru Nakazawa; Kousuke Noda; Lama Almulki; Shinsuke Miyahara; Shintaro Nakao; Yasuhiro Ito; Haicheng She; Riichiro Kohno; Norman Michaud; Tatsuro Ishibashi; Ali Hafezi-Moghadam; Andrew D Badley; Guido Kroemer; Joan W Miller
Journal:  J Clin Invest       Date:  2008-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.